Track record · closed signal

Halozyme Therapeutics, Inc. (HALO) — closed signal from September 24, 2025

Partial Published before the outcome was known, scored automatically when the window closed on December 23, 2025.

Predicted vs. what happened

HALO price · publication thesis → realized outcomesplit-adjusted
$77.39 Published $95.96 Target $68.36 Window close $78.33 Peak
$75.50 – $78.50Entry zone — fair-value band
$77.39Published — price the day we called it
$95.96Target — the price the thesis aimed for
$78.33Peak — highest point inside the window, not a realized return
$68.36Window close — end-of-window price, context only

What happened

Partial

Reached 5% of the predicted growth at its peak, without hitting the target.

Peak price
$78.33
peak on September 24, 2025 — not a realized return
Peak gain
+1.2%
peak, from the publication price
Window close
$68.36
end-of-window price, context only
Days to target
—
Window
September 24, 2025 – December 23, 2025

The thesis — published September 24, 2025

Predicted growth
+24%
over the measurement window
Target price
$95.96
the price the thesis aimed for
Entry zone
$75.50 – $78.50
the fair-value band we waited for
Price at publication
$77.39
published September 24, 2025
Confidence
85%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

HALO keeps delivering while the trend points to buying dips. A research note flagged sales up 35% compared to last year, shares up 63.8% this year, and 2025 profit estimates raised to $6.18, showing its ENHANZE partner model is working. The uptrend looks intact, with better entries on pullbacks toward a rising recent average price. Over 0-3 months, launches and estimate hikes could push shares to the low 90s, with exits below recent lows.

Primary drivers

  • Sales and profits are rising, and 2025 profit forecasts moved higher now
  • More partner drug launches mean ENHANZE gets used across more medicines
  • The uptrend looks solid, so pullbacks could offer better entry points
  • Near-term mood across biotech is favorable, helping demand for shares

How it played out

HALO: thesis missed the target

Lyra published HALO at $77.39 on September 24, 2025, with expected growth of 24% and a target of $95.96. The thesis pointed to rising sales and profits, higher 2025 profit forecasts, more partner drug launches using ENHANZE, a solid uptrend, and favorable near-term biotech demand.

Inside the window, HALO peaked at $78.33 on September 24, with a peak gain of 1.2%. It never reached the target. By December 23, 2025, it ended at $68.36. The published thesis did not play out in price terms.

What happened during the window

On November 12, 2025, Investor's Business Daily wrote that Halozyme had reported better than expected third-quarter earnings on November 3. On December 23, 2025, the same outlet reported that Halozyme's Relative Strength Rating improved from 66 to 71.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HALO signals